Christoph Stephan, MD
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L14-0591.
Stephan C. Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. Ann Intern Med. 2015;162:460-461. doi: 10.7326/L15-5066
Download citation file:
Published: Ann Intern Med. 2015;162(6):460-461.
TO THE EDITOR:
A design characteristic in Lennox and colleagues' trial (1) allowed patients to switch the third antiretroviral compound within the ACTG (AIDS Clinical Trials Group) A5257 open-label trial; this method is distinct from that of historical randomized clinical comparisons. The aim of this protocol specification may have been to enable an antiretroviral therapy switch for patients facing nonserious adverse events, thus approaching a real-life clinical setting. A prerequisite for an unbiased observation is the free dispensing of all administered study drugs. However, a booster of ritonavir, 100 mg/d, was not provided for participants randomly assigned to a protease inhibitor regimen within the study, and whether affected patients were reimbursed for these costs remains unclear.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only